{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:17:24Z","timestamp":1790320644918,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.vaccine.2015.07.019","type":"journal-article","created":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T01:18:00Z","timestamp":1437009480000},"page":"4414-4421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Serum bactericidal antibody assays \u2013 The role of complement in infection and immunity"],"prefix":"10.1016","volume":"33","author":[{"given":"E.D.G.","family":"McIntosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Br\u00f6ker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wassil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Welsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2015.07.019_bib0480","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1128\/CMR.00048-09","article-title":"Infections of people with complement deficiencies and patients who have undergone splenectomy","volume":"43","author":"Ram","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"10.1016\/j.vaccine.2015.07.019_bib0485","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1128\/IAI.01224-13","article-title":"Outer membrane protein P5 is required for resistance of nontypeable Haemophilus influenzae to both the classical and alternative complement pathways","volume":"82","author":"Rosadini","year":"2014","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2015.07.019_bib0490","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/icb.2013.28","article-title":"Full functional activity of SSL7 requires binding of both complement C5 and IgA","volume":"91","author":"Lorenz","year":"2013","journal-title":"Immunol Cell Biol"},{"issue":"5","key":"10.1016\/j.vaccine.2015.07.019_bib0495","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/mmi.12311","article-title":"A surface-exposed neuraminidase affects complement resistance and virulence of the oral spirochaete Treponema denticola","volume":"89","author":"Kurniyati","year":"2013","journal-title":"Mol Microbiol"},{"issue":"4.","key":"10.1016\/j.vaccine.2015.07.019_bib0500","article-title":"CspA from Borrelia burgdorferi inhibits the terminal complement pathway","volume":"4","author":"Hallstrom","year":"2013","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.vaccine.2015.07.019_bib0505","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1128\/IAI.01094-13","article-title":"Versatile roles of CspA orthologs in complement inactivation of serum-resistant Lyme disease spirochetes","volume":"82","author":"Hammerschmidt","year":"2014","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.vaccine.2015.07.019_bib0510","doi-asserted-by":"crossref","first-page":"e45132","DOI":"10.1371\/journal.pone.0045132","article-title":"Opc expression, LPS immunotype switch and pilin conversion contribute to serum resistance of unencapsulated meningococci","volume":"7","author":"Hubert","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0515","doi-asserted-by":"crossref","first-page":"e1001027","DOI":"10.1371\/journal.ppat.1001027","article-title":"The meningococcal vaccine candidate Neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement","volume":"6","author":"Lewis","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0520","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","article-title":"The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance","volume":"177","author":"Madico","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0525","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.4049\/jimmunol.176.12.7566","article-title":"Functional significance of factor H binding to Neisseria meningitidis","volume":"176","author":"Schneider","year":"2006","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2015.07.019_bib0530","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1365-2958.2011.07876.x","article-title":"Meningococcal surface fibril (Msf) binds to activated vitronectin and inhibits the terminal complement pathway to increase serum resistance","volume":"82","author":"Griffiths","year":"2011","journal-title":"Mol Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2015.07.019_bib0535","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/mmi.12164","article-title":"Haemophilus influenzae acquires vitronectin via the ubiquitous Protein F to subvert host innate immunity","volume":"87","author":"Su","year":"2013","journal-title":"Mol Microbiol"},{"issue":"7","key":"10.1016\/j.vaccine.2015.07.019_bib0540","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/infdis\/jis939","article-title":"Serine protease PKF of Acinetobacter baumannii results in serum resistance and suppression of biofilm formation","volume":"207","author":"King","year":"2013","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2015.07.019_bib0545","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.4049\/jimmunol.1200386","article-title":"Dihydrolipoamide dehydrogenase of Pseudomonas aeruginosa is a surface-exposed immune evasion protein that binds three members of the factor H family and plasminogen","volume":"189","author":"Hallstrom","year":"2012","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2015.07.019_bib0550","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/IAI.00800-13","article-title":"Response of extraintestinal pathogenic Escherichia coli to human serum reveals a protective role for Rcs-regulated exopolysaccharide colonic acid","volume":"82","author":"Miajlovic","year":"2014","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2015.07.019_bib0555","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.4049\/jimmunol.1201145","article-title":"The Yersinia pseudotuberculosis outer membrane Ail recruits the human complement regulatory protein factor H","volume":"189","author":"Ho","year":"2012","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2015.07.019_bib0560","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ajhg.2011.05.011","article-title":"Disease-causing mutations in genes of the complement system","volume":"88","author":"Degn","year":"2011","journal-title":"Am J Hum Genet"},{"issue":"38","key":"10.1016\/j.vaccine.2015.07.019_bib0565","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1016\/j.vaccine.2013.06.009","article-title":"fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations","volume":"31","author":"Giuntini","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0570","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.4049\/jimmunol.1103748","article-title":"The relative roles of Factor H binding protein, Neisserial Surface Protein A, and Lipooligosaccharide Sialylation in regulation of the alternative pathway of complement on meningococci","volume":"188","author":"Lewis","year":"2012","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2015.07.019_bib0575","doi-asserted-by":"crossref","first-page":"e00339","DOI":"10.1128\/mBio.00339-13","article-title":"Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis","volume":"4","author":"Lewis","year":"2013","journal-title":"mBio"},{"issue":"6","key":"10.1016\/j.vaccine.2015.07.019_bib0580","first-page":"134","article-title":"Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing","volume":"26","author":"Kugelberg","year":"2008","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2015.07.019_bib0585","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/infdis\/jit239","article-title":"Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H binding protein vaccines","volume":"208","author":"Konar","year":"2013","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2015.07.019_bib0590","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1086\/528994","article-title":"Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen","volume":"197","author":"Welsch","year":"2008","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2015.07.019_bib0595","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/IAI.05956-11","article-title":"Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor H binding protein","volume":"80","author":"Giuntini","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0600","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I: The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2015.07.019_bib0605","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0610","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization \u2013 international meeting report Emory University, Atlanta, Georgia, United States, 16\u201317 March 2005","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0615","series-title":"Vaccines","first-page":"399","article-title":"Meningococcal vaccines","author":"Granoff","year":"2008"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0620","first-page":"72","article-title":"Requirements for meningococcal polysaccharide vaccine (requirements for biological substances No. 23)","volume":"594","author":"World Health Organization","year":"1976","journal-title":"WHO Tech Rep Ser"},{"issue":"11","key":"10.1016\/j.vaccine.2015.07.019_bib0625","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1086\/508776","article-title":"Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization","volume":"43","author":"Snape","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0630","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1128\/CDLI.8.3.616-623.2001","article-title":"Importance of complement source in measuring meningococcal bactericidal titres","volume":"8","author":"Santos","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0635","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom. Re-evaluation of correlates of protection","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0640","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1128\/CVI.00341-07","article-title":"Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal activity","volume":"14","author":"Welsch","year":"2007","journal-title":"Clin Vaccine Immunol"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2015.07.019_bib0645","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","article-title":"Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story","volume":"20","author":"Miller","year":"2001","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2015.07.019_bib0650","first-page":"213","article-title":"Estimating the burden of serogroup C meningococcal disease in England and Wales","volume":"5","author":"Davison","year":"2002","journal-title":"Commun Dis Public Health"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0655","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(00)03594-7","article-title":"Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England","volume":"357","author":"Ramsay","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0660","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0665","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated post-licensure surveillance of meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection and modelling predictions of the duration of herd immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"7385","key":"10.1016\/j.vaccine.2015.07.019_bib0670","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis","volume":"326","author":"Ramsay","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0675","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0264-410X(02)00630-8","article-title":"Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era","volume":"21","author":"Trotter","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0680","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJM197709292971302","article-title":"Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age","volume":"297","author":"Peltola","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0685","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.vaccine.2005.01.058","article-title":"The concept of \u201ctailor-made\u201d, protein-based, outer membrane vesicle vaccines against meningococcal disease","volume":"23","author":"Holst","year":"2005","journal-title":"Vaccine"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.07.019_bib0690","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0695","series-title":"The immunological basis for immunization series. Module 15. Meningococcal disease","first-page":"7","author":"Borrow","year":"2010"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0700","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection \u2013 serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2015.07.019_bib0705","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1128\/IAI.40.1.257-264.1983","article-title":"Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide","volume":"40","author":"Zollinger","year":"1983","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2015.07.019_bib0710","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/sji.12150","article-title":"Avidity of IgG antibodies against meningococcal serogroup A polysaccharide and correlations with bactericidal activity in sera from meningitis patients and controls from Ethiopia","volume":"79","author":"Medhane","year":"2014","journal-title":"Scand J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2015.07.019_bib0715","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1128\/CVI.00241-06","article-title":"Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assay","volume":"14","author":"Harris","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0720","first-page":"263","volume":"vol. 71","author":"Plested","year":"2002"},{"issue":"3","key":"10.1016\/j.vaccine.2015.07.019_bib0725","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.ijid.2012.10.001","article-title":"Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus conjugate vaccines (MenACWY-TT)","volume":"17","author":"Ostergaard","year":"2013","journal-title":"Int J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2015.07.019_bib0730","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.4161\/hv.22165","article-title":"A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2015.07.019_bib0735","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4161\/hv.7.2.14068","article-title":"Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults","volume":"7","author":"Bermal","year":"2011","journal-title":"Hum Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2015.07.019_bib0740","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/INF.0b013e3182787bff","article-title":"Three-year antibody persistence and safety after a single dose of combined Haemophilus influenzae type b (Hib)- Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers","volume":"32","author":"Booy","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"10.1016\/j.vaccine.2015.07.019_bib0745","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/INF.0b013e318269433a","article-title":"Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine","volume":"31","author":"Tejedor","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"10.1016\/j.vaccine.2015.07.019_bib0750","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/INF.0b013e318262528c","article-title":"Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study","volume":"31","author":"Khatami","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.vaccine.2015.07.019_bib0755","doi-asserted-by":"crossref","first-page":"e1375","DOI":"10.1542\/peds.2009-2992","article-title":"Immunogenicity and safety of H. influenzae type b-N. meningitidis C\/Y conjugate vaccine in infants","volume":"127","author":"Bryant","year":"2011","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.vaccine.2015.07.019_bib0760","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/INF.0b013e3181c3ce88","article-title":"Randomized trial to assess the immunogenicity and safety of an investigational Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants","volume":"29","author":"Marchant","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2015.07.019_bib0765","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1097\/INF.0b013e318279ac38","article-title":"Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents","volume":"32","author":"Jacobson","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"18","key":"10.1016\/j.vaccine.2015.07.019_bib0770","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1016\/j.vaccine.2010.02.045","article-title":"Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines","volume":"28","author":"Arguedas","year":"2010","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2015.07.019_bib0775","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.vaccine.2009.10.104","article-title":"Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2\u201310 years of age","volume":"28","author":"Black","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0780","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1086\/599117","article-title":"Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents","volume":"49","author":"Jackson","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2015.07.019_bib0785","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/INF.0b013e31818e037d","article-title":"Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine infants","volume":"28","author":"Perrett","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"10.1016\/j.vaccine.2015.07.019_bib0790","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/INF.0b013e318268dfe4","article-title":"Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter Phase III studies","volume":"31","author":"Pina","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2015.07.019_bib0795","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/INF.0b013e31820e6e02","article-title":"Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year olds is noninferior to a licensed ACWY polysaccharide vaccine with an acceptable safety profile","volume":"30","author":"Memish","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2015.07.019_bib0800","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/INF.0b013e3182054ab9","article-title":"Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age","volume":"30","author":"Baxter","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0805","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA"},{"issue":"9869","key":"10.1016\/j.vaccine.2015.07.019_bib0810","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0815","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2015.07.019_bib0820","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.4161\/hv.25505","article-title":"Persistence of antibodies in adolescents 18-24 months after immunization with one, two or three doses of 4CMenB meningococcal serogroup B vaccine","volume":"9","author":"Santolaya","year":"2013","journal-title":"Hum Vacc Immunother"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0825","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.vaccine.2015.07.019_bib0830","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4161\/hv.7.6.15482","article-title":"The first use of an investigational meningococcal serogroup B vaccine (4CMenB) in humans","volume":"7","author":"Toneatto","year":"2011","journal-title":"Human Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2015.07.019_bib0835","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/CVI.00304-10","volume":"18","author":"Kimura","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"40","key":"10.1016\/j.vaccine.2015.07.019_bib0840","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1016\/j.vaccine.2014.07.049","article-title":"A randomized, phase I\/II trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants","volume":"32","author":"Martinon-Torres","year":"2014","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2015.07.019_bib0845","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/INF.0b013e31827b0d24","article-title":"A randomized, controlled, phase I\/II trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents","volume":"32","author":"Nissen","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"10.1016\/j.vaccine.2015.07.019_bib0850","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/INF.0b013e31826327e4","article-title":"Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a Phase I randomized-controlled clinical trial","volume":"31","author":"Marshall","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"43","key":"10.1016\/j.vaccine.2015.07.019_bib0855","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1016\/j.vaccine.2012.07.065","article-title":"A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation Phase I trial","volume":"30","author":"Richmond","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0860","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/IAI.01191-08","article-title":"Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera","volume":"77","author":"Granoff","year":"2009","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2015.07.019_bib0865","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.vaccine.2011.10.068","article-title":"Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source","volume":"30","author":"Gill","year":"2011","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2015.07.019_bib0870","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1016\/j.vaccine.2010.05.014","article-title":"Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus","volume":"28","author":"Giuliani","year":"2010","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2015.07.019_bib0875","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/IAI.6.5.651-656.1972","article-title":"Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and III","volume":"6","author":"Robbins","year":"1972","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2015.07.019_bib0880","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1128\/IAI.8.6.896-900.1973","article-title":"Polysaccharides of the genus Bacillus cross-reactive with the capsular polysaccharides of Diplococcus pneumoniae type III, Haemophilus influenzae type b, and Neisseria meningitidis group A","volume":"8","author":"Myerowitz","year":"1973","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2015.07.019_bib0885","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1128\/IAI.13.6.1654-1662.1976","article-title":"Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide","volume":"13","author":"Vann","year":"1976","journal-title":"Infect Immun"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2015.07.019_bib0890","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jim.2013.02.007","article-title":"Development of a large scale human complement source for use in bacterial immunoassays","volume":"39","author":"Brookes","year":"2013","journal-title":"J Immunol Methods"},{"issue":"6","key":"10.1016\/j.vaccine.2015.07.019_bib0895","doi-asserted-by":"crossref","first-page":"E246","DOI":"10.1111\/j.1399-3046.2011.01585.x","article-title":"Immunogenicity of meningococcal C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy","volume":"16","author":"Zlamy","year":"2012","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0900","series-title":"Abstract P12 of the XIXth International Pathogenic Neisseria Conference (IPNC)","article-title":"Effects of the Eculizumab (Soliris\u00ae), on the meningococcal serogroup B (MenB) serum bactericidal antibody (SBA) assay","author":"Bai","year":"2014"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0905","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1182\/blood-2014-07-589366","article-title":"Eculizumab fails to inhibit generation of C5a in vivo","volume":"124","author":"Burwick","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.vaccine.2015.07.019_bib0910","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1128\/CVI.05655-11","article-title":"Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction","volume":"19","author":"Ishola","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2015.07.019_bib0915","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1128\/CVI.05354-11","article-title":"Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood","volume":"18","author":"Khatami","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0920","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diag Lab Immunol"},{"key":"10.1016\/j.vaccine.2015.07.019_bib0925","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/CDLI.12.8.970-976.2005","article-title":"Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine","volume":"12","author":"Borrow","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2015.07.019_bib0930","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/CVI.05028-11","article-title":"Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis","volume":"18","author":"Mak","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2015.07.019_bib0935","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1128\/CVI.00007-09","article-title":"Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity","volume":"16","author":"Plested","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2015.07.019_bib0940","doi-asserted-by":"crossref","first-page":"e49147","DOI":"10.1371\/journal.pone.0049147","article-title":"The stability of complement-mediated bactericidal activity in human serum against Salmonella","volume":"7","author":"O'Shaughnessy","year":"2012","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.vaccine.2015.07.019_bib0945","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1128\/IAI.72.10.5903-5909.2004","article-title":"Naturally acquired passive protective activity against Neisseria meningitidis group C in the absence of serum bactericidal activity","volume":"72","author":"Welsch","year":"2004","journal-title":"Infect Immun"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.07.019_bib0950","doi-asserted-by":"crossref","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","article-title":"Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15009536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15009536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T04:40:21Z","timestamp":1652848821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15009536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":95,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0264410X15009536"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.07.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum bactericidal antibody assays \u2013 The role of complement in infection and immunity","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}